BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed herewith Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2020. BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2020. Kindly take the same on record. BLISS GVS PHARMA LTD. - 506197 - Shareholding for the Period Ended June 30, 2020
Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here BLISS GVS PHARMA LTD. - 506197 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- Aditi BhattDesignation :- Company Secretary and Compliance Officer BLISS GVS PHARMA LTD. - 506197 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed disclosure of Related Party Transactions on the basis on consolidated financial statements for the year ended March 31, 2020. Kindly take the above information on record. BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window
This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ('the Company') will remain closed for all the Designated Persons and their immediate relatives of the Company with effect from Wednesday, July 01, 2020 until 48 hours after the announcement of the unaudited financial results of the Company for the quarter ended June 30, 2020. Accordingly, all Designated Persons and their immediate relatives are advised not to trade (buy or sell or pledge etc.) in the securities/shares of the Company during the aforesaid period of closure of Trading Window. BLISS GVS PHARMA LTD. - 506197 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBLISS GVS PHARMA LTD. 2CINL24230MH1984PLC034771 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 5219.44 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Aditi Bhatt Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Vipul Thakkar Designation: Chief Financial Officer EmailId: [email protected] Date: 26/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. BLISS GVS PHARMA LTD. - 506197 - Board recommends Dividend
Bliss GVS Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 16, 2020, inter alia, has recommended a dividend of 50% i.e. 0.50 paisa per equity share on face value of Re. 1/- each for the financial year ended March 31, 2020, subject to approval of the shareholders in the forthcoming Annual General Meeting (ACM) of the Company. BLISS GVS PHARMA LTD. - 506197 - Outcome Of Board Meeting Held On 16Th June, 2020- Re-Classification Of Shareholding From 'Promoter & Promoter Group Category' To 'Public Category' And/Or Remove Their Names From 'Promoter & Promoter Group Category'
We would like to inform you that, Board Meeting of the Company was held today i.e. on Tuesday, June 16, 2020 at registered office of the Company. In pursuant to Regulation 31A SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the Re-classification of shareholding of following persons from 'Promoter & Promoter Group Category' to 'Public Category' and/or Remove their Names from 'Promoter & Promoter Group Category' of the Company based on their request letters received. 1) Gautam Rasiklal Ashra 2) Arjun Gautam Ashra 3) Antara Gautam Ashra 4) Mamta Gautam Ashra 5) Gautam Rasiklal Ashra on behalf of Arjun & Antara Trust 6) Vijayaben Kanji Ashra 7) Kanji Forex Private Limited 8) Kanji Pitamber Forex Private Limited 9) Genteel Trading Company Private Limited 10) Mangesh Ghanashyam Wagle 11) Mangesh Ghanashyam Wagle HUF